Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
Who at Sofinnova Venture Partners can lead a round?
6 named
6 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
Ajax Health II, Ajax Health III, Alcresta Therapeutics, ALIMERA SCIENCES, AVEDRO, Bardy Diagnostics, CASTLE BIOSCIENCES, CleanSlate Centers, First Aid Beverages, Home Hospital Newco, Magnolia Medical Technologies, MELINTA THERAPEUTICS, INC. /NEW/, Nomad Health, Strongbridge Biopharma plc, Trice Medical, Venus Concept, Venus Concept
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Manufacturing & industrials1 · 2%
Real estate & proptech1 · 2%
Telecom & networking1 · 2%
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Sofinnova Venture Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
5
Aeovian Pharmaceuticals, Apellis Pharmaceuticals, Checkmate Pharmaceuticals, Marea Therapeutics, RayzeBio
A shared board seat: a company where filings name a Sofinnova Venture Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
